Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1
Ragunathan P, Dick T, Grüber G
Antimicrobial agents and chemotherapy · 2022-04
Abstract
New drug targets and molecules with bactericidal activity are needed against the respiratory mycobacterial pathogen Mycobacterium abscessus. Employing a lead repurposing strategy, the antituberculosis compound GaMF1 was tested against M. abscessus. Whole-cell and ATP synthesis assays demonstrated that GaMF1 inhibits growth and kills M. abscessus by targeting the F-ATP synthase. GaMF1's anti-M. abscessus activity increased in combination with clofazimine, rifabutin, or amikacin. The study expands the repertoire of anti-M. abscessus compounds targeting oxidative phosphorylation.
MeSH terms
- Humans
- Tuberculosis
- Adenosine Triphosphate
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Microbial Sensitivity Tests
- Mycobacterium Infections, Nontuberculous
- Mycobacterium abscessus